Solid masses of the pancreas represent a variety of benign and malignant neoplasms of the exocrine and endocrine tissues of the pancreas. A tissue diagnosis is often required to direct therapy in the face of uncertain diagnosis or if the patient is not a surgical candidate either due to advanced disease or comorbidities. Endoscopic ultrasound (EUS) is a relatively new technology that employs endoscopy and high-frequency ultrasound (US). EUS involves imaging of the pancreatic head and the uncinate from the duodenum and imaging of the body and tail from the stomach. It has been shown to be a highly sensitive method for the detection of pancreatic masses. It is superior to extracorporeal US and computed tomographic (CT) scans, especially when the pancreatic tumor is smaller than 2-3 cm. Although EUS is highly sensitive in detecting pancreatic solid masses, its ability to differentiate between inflammatory masses and malignant disease is limited. Endoscopic retrograde cholangiopancreatography (ERCP) brushing, CT-guided biopsies, and transabdominal ultrasound (US) have been the standard nonsurgical methods for obtaining a tissue diagnosis of pancreatic lesions, but a substantial false-negative rate has been reported. Transabdominal US-guided fine-needle aspiration biopsy (US-FNAB) has been used for tissue diagnosis in patients with suspected pancreatic carcinoma. It has been shown to be highly specific, with no false-positive diagnoses. With the advent of curvilinear echoendoscopes, transgastric and transduodenal EUS-FNAB of the pancreas have become a reality EUS with FNAB has revolutionized the ability to diagnose and stage cancers of the gastrointestinal tract and assess the pancreas. Gastrointestinal cancers can be looked at with EUS and their depth of penetration into the intestinal wall can be determined. Any suspicious appearing lymph nodes can be biopsied using EUS/FNAB. The pancreas is another organ that is well visualized with EUS. Abnormalities such as tumors and cysts of the pancreas can be carefully evaluated using EUS and then biopsied with FNAB. There are many new applications of EUS using FNAB. Researchers are looking to deliver chemotherapeutics into small pancreatic cancers and cysts. Nerve blocks using EUS/FNAB to inject numbing medicines into the celiac ganglia, a major nerve cluster, are now routinely performed in patients with pain due to pancreatic cancer. The aim of this study is to perform a review of the literature regarding the usefulness of EUS/FNAB in the diagnosis of pancreatic adenocarcinoma.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. RAUT CP GRAU AM STAERKEL GA et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg. 2003; 7(1):118-28.
2. ELOUBEIDI MA CHEN VK ISAM A ELTOUM IA et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. The American Journal of Gastroenterology .2003; 98:2663-8.
3. HAREWOOD G WIERSEMA MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. The American Journal of Gastroenterology.2002; 97: 1386-91.
4. YLAGAN LR EDMUNDOWICZ S KASAL K et al. Endoscopic ultrasound guided fine-needle aspiration cytology of pancreatic carcinoma. A 3-year experience and review of the literature. Cancer Cytopathology. 2002; 96(6):362-9.
5. FRITSCHER-RAVENS A IZBICKI JB SRIRAM VJP et al. Endosonography-guided fine-needle aspiration cytology extending the indication for organ-preserving pancreatic surgery. The American Journal of Gastroenterology.2000; 95:2255-60.
6. AFIFY AM AL-KHAFAJI BM KIM B SCHEIMAN JM et al. Endoscopic ultrasound-guided fine needle aspiration of the pancreas. Diagnostic utility and accuracy. Acta Cytologica. 2003: 47(3):341-8.
7. MICHAEL JONATHAN HEWITT MCPHAIL MRCP LUCIA POSSAMAI AMEET DHAR PANAGIOTIS VLAVIANOS KEVIN J. MONAHAN. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointestinal Endoscopy.2012; 75(2):319-31.
8. DEMAY RM. The art and science of cytopathology: pancreas. Chicago: ASCP Press. 1996: 1059-69.
9. NIEDERHUBER JE MURRAY F. BRENNAN HERMAN R. MENCK . The national cancer data base report on pancreatic cancer. Cancer. 1995; 76 (9): 1671-77.
10. BECKINGHAM IJ. ABC of liver pancreas and gallbladder 1st ed. London: BMJ: 2001.
11. GREENBLATT DY KELLY KJ RAJAMANICKAM V. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Annals of Surgical Oncology. 2011; 18(8):2126-35.
12. NOH KW WALLACE MB. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic adenocarcinoma. MedGenMed. 2005; 7(2): 15- 19.
13. BRET PM VIVIANE NICOLET V LABADIE M. Percutaneous fine-needle aspiration biopsy of the pancreas. Diagnostic Cytopathology.1986; 2(3):221-7.
14. BRANDT KR CHARBONEAU JW STEPHENS DH et al. CT- and US-guided biopsy of the pancreas. Radiology. 1993; 187: 99-104.
15. LEE JG LEUNG J. Tissue sampling at ERCP in suspected pancreatic cancer. Gastrointestinal Endoscopy Clinics of North America. 1998; 8(1):221-35.
16. PAQUIN SC GARIÉPY G LEPANTO L et al. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest Endosc. 2005 Apr; 61(4):610-1.
17. MITCHELL ML CARNEY CN. Cytologic criteria for the diagnosis of pancreatic carcinoma. American Journal of Clinical Pathology. 1985; 83(2):171-6.
18. COHEN MB EGERTER DP HOLLY EA AHN DK MILLER TR. Pancreatic adenocarcinoma: Regression analysis to identify improved cytologic criteria. Diagnostic Cytopathology.1991; 7(4):341-5.
19. ROBINS DB KATZ RL EVANS DB ATKINSON EN GREEN L. Fine needle aspiration of the pancreas. In quest of accuracy. Acta Cytologica. 1995; 39(1):1-10.
20. FEKETE PS NUNEZ C DEBORAH A. PITLIK DA. Fine-needle aspiration biopsy of the pancreas: A study of 61 cases. Diagnostic Cytopathology. 1986; 2(4):301-6.
21. AL-KAISI N SIEGLER EE. Fine needle aspiration cytology of the pancreas. Acta Cytologica. 1989; 33(2):145-52.
22. KOCJAN G RODE J LEES WR. Percutaneous fine needle aspiration cytology of the pancreas: advantages and pitfalls. J Clin Pathol 1989; 42:341-7.
23. BRITS CJ FRANZ RC. Pale nodular nuclei-diagnostic of adenocarcinoma of the pancreas? Acta Cytologica. 1976; 20(5):462-8.
24. LIN F STAERKEL GM. Cytologic criteria for well differentiated adenocarcinoma of the pancreas in fine-needle aspiration biopsy specimens. Cancer Cytopathology. 2003; 99(1):44-50.
25. LIN F JIANHUI S HAIYAN L et al. Diagnostic utility of S100P and von Hippel-Lindau Gene Product (pVHL) in pancreatic adenocarcinoma - with implication of their roles in early tumorigenesis. American Journal of Surgical Pathology. 2008; 32(1):78-91.
26. LEVY M LIN F XU H DHALL D BETSY O. SPAULDING BO WANG HL. S100P von Hippel-Lindau gene product and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Human Pathology. 2010; 41(9):1210-1219.
27. ZHAO H MANDICH D RICHARD W. CARTUN RW LIGATO S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagnostic Cytopathology.2007; 35(11):700-4.
28. KYOKO K NOBUYUKI O SEISHIRO M MASASHI S MANABU T TOSHIO M. Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas. Hepatobiliary Pancreat Dis Int. 2008; 7(1):86-90.
29. AGARWAL B LUDWIG OJ BRIAN T. COLLINS BT CORTESE C. Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma. Clinical Gastroenterology and Hepatology. 2008; 6(12):1425-1431.
30. MCCARTHY DM MAITRA A; ARGANI P et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: Mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Applied Immunohistochemistry & Molecular Morphology. 2003; 11(3):238-43.
31. HASSAN R LASZIK ZG MEGAN LERNER M RAFFELD M POSTIER R BRACKETT D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. American Journal of Clinical Pathology.2005; 124: 838-845.
32. KARANJAWALA ZE ILLEI PB ASHFAQ R et al. New markers of pancreatic cancer identified through differential gene expression analyses: Claudin 18 and Annexin A8. Am J Surg Pathol. 2008; 32(2): 188-196.
33. DE LOTT LB MORRISON C SUSTER S COHN DE FRANKEL WL. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med. 2005; 129(9):1100-5.
34. GOLDSTEIN NS BASSI D. Cytokeratins 7 17 and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001; 115(5):695-702.
35. CHU PG SCHWARZ RE LAU SK YEN Y WEISS L. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of vater adenocarcinoma: Application of CDX2 CK17 MUC1 and MUC2. American Journal of Surgical Pathology. 2005; 29(3):359-367.
36. LAU SK PRAKASH S GELLER SA ALSABEH R. Comparative immunohistochemical profile of hepatocellular carcinoma cholangiocarcinoma and metastatic adenocarcinoma. Human Pathology 2002; 33(12):1175-1181.
37. KOHJI NAGATA MICHIKO HORINOUCHI MIYUKI SAITOU et al. Mucin expression profile in pancreatic cancer and the precursor lesions. Journal of Hepato-Biliary-Pancreatic Surgery.2007; 14(3):243-254.
38. NIRAG JHALA DARSHANA JHALA SELWYN M. VICKERS et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates: A translational research application. American Journal of Clinical Pathology. 2006: 126:572-9.
39. TAMAR A. GIORGADZE HEATHER PETERMAN ZUBAIR BALOCH et al. Diagnostic utility of mucin profile in fineneedle aspiration specimens of the pancreas: An immunohistochemical study with surgical pathology correlation. Cancer Cytopathology. 2006; 108(3):186-197.
40. KOSARAC O TAKEI H ZHAI QJ SCHWARTZ MR MODY DR. S100P and XIAP expression in pancreatic ductal adenocarcinoma: Potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology. Acta Cytologica 2011; 55: 142-148.
41. WACHTER DL SCHLABRAKOWSKI A HOEGEL J KRISTIANSEN G HARTMANN A RIENER MO. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. American Journal of Surgical Pathology. 2011; 35(6):873-877.
42. LIU H SHI J ANANDAN V WANG HL DIEHL D BLANSFIELD J GERHARD G LIN F. Reevaluation and identification of the best immunohistochemical panel (pVHL Maspin S100P IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 2012;136(6):601-9.
43. DANIEL C. DIM FENG JIANG QI QIU TING PETER DARWIN WILLIAM H. RODGERS HONG QI PENG. The usefulness of S100P mesothelin fascin prostate stem cell antigen and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagnostic Cytopathology 2014; 42(3):193-9.
44. TAKAHASHI K YAMAO K OKUBO K et al. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest. Endosc. 2005; 61: 76-9.
45. HOSODA W TAKAGI T MIZUNO N et.al. Diagnostic approach to pancreatic tumor with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol. Int. 2010; 60: 358-64.
46. DENG H SHI J WILKERSON M FUPREE W LIN F. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine needle aspiration biopsy specimens. Am. J. Clin. Pathol. 2008; 129: 81-8.
47. GIORGADZE TA PETERMAN H BALOCH ZW et al. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas. Cancer Cytopathol. 2006; 108: 186-97.
48. KROEP JR LOVES WJ VAN DER WILT CL et al. Pretreatment deoxycytidine linase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 2002; 1: 371-6.
49. ASHIDA R NAKATA B SHIGEKAWA M et al. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasoundguided fine-needle aspiration biopsy of unresectable pancreatic cancer. J. Exp. Clin. Cancer Res. 2009; 28: 83.
50. GIOVANNETTI E DEL TACCA M MEY V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006; 66: 3928-35.
51. FUJITA H OHUCHIDA K MIZUMOTO K et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 2010; 12: 807-10.
52. YOSHINAGA S SUZUKI H ODA I SAITO Y. Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses. Dig Endosc. 2011; 23 Suppl 1:29-33.